Hematology and oncology

  • Leukemia
  • Lymphoma
  • Multiple myeloma
  • Aplastic anemia
  • Pancytopenia
  • Amyloidosis
  • Fludarabine treatment
  • Chronic GVHD (graft versus host disease)

Transplant recipient

  • Allogeneic bone marrow transplant or stem cell transplant
  • CMV negative recipient with CMV negative donor
  • 7 days pre-transplant to 100 days post-transplant

Congenital immune deficiencies

  • Di George’s syndrome
  • Congenital heart disease
  • Congenital cell-mediated immune deficiency
  • Severe combined immune deficiency
  • Wiskott-Aldrich syndrome
  • Purine nucleotide phosphorylase deficiency
  • Reticular dysgenesis
  • Adenosine deaminase deficiency
  • MCH I or MCH II deficiency
  • Leukocyte adhesion molecular deficiency
  • Cell-mediated immune deficiency NOS

Pediatric patients

  • All neonates
  • Congenital heart disease
  • Intrauterine transfusions (IUT)
  • Open heart surgery within the past year
  • Solid tumors
    • Wilm’s tumor
    • Ewings sarcoma
    • Hepatoblastoma
    • Neuroblastoma
    • Retinoblastoma
    • Osteogenic sarcoma
    • Rhabdomyosarcoma
    • Intracranial malignancy
    • Primitive neuroectodermal tumor (PNET)
    • Histiocytosis X (Langerhan’s cell histiocytosis)

Other

  • Pregnant patients (excluding delivery)
  • Recipient of HLA-matched platelets
  • Recipient of a directed donation